Oncternal Therapeutics Shares Are Trading Lower After the Company Announced It Will Discontinue Its Clinical Trials for ONCT-535 and ONCT-808 Due to a Lack of Meaningful Results and High Capital Requirements.
Oncternal Therapeutics Shares Are Trading Lower After the Company Announced It Will Discontinue Its Clinical Trials for ONCT-535 and ONCT-808 Due to a Lack of Meaningful Results and High Capital Requirements.
oncternal therapeutics宣布将停止ONCt-535和ONCt-808的临床试验，原因是缺乏意义深远的结果和高额资本需求，其股价已经下跌。
Oncternal Therapeutics Shares Are Trading Lower After the Company Announced It Will Discontinue Its Clinical Trials for ONCT-535 and ONCT-808 Due to a Lack of Meaningful Results and High Capital Requirements.
oncternal therapeutics宣布将停止ONCt-535和ONCt-808的临床试验，原因是缺乏意义深远的结果和高额资本需求，其股价已经下跌。